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The same acute-phase serum was test-
ed for flavivirus RNA by seminested
reverse transcription–polymerase
chain reaction (RT-PCR) by using fla-
vivirus consensus primers PF1S and
PF2R as previously described (1) in
conjunction with the sense primer
PF3S (GCIATHTGGTAYATGTG-
GYT). Attempts to isolate viruses by
using C6/36 and Vero cells were
unsuccessful, which might be expect-
ed given the delay between the onset
of symptoms and specimen collection.
Sequence analysis of the 163-bp
(primers excluded) PCR product
(GenBank accession no. AY862501)
showed 89%–99.4% range of homolo-
gy with 34 dengue 3 virus strains by
using the BLAST nucleotide program.
Similarities obtained with sequences
of dengue virus 1, 2, and 4 were <87%.
Phylogenetic analysis performed with
the patient sequence together with
homologous sequences from dengue
viruses and other flaviviruses showed
that it corresponded to dengue 3 virus
species. RT-PCR amplification on the
convalescent-phase serum was nega-
tive. Based on World Health
Organization criteria, the patient was
diagnosed with dengue fever (2). The
patient’s interview showed a previous
dengue fever episode in Haiti in 1995
and a previous malaria episode in
Burundi in 2002, but biologic confir-
mation was not available, and serum
was not collected before this episode.
Therefore, we could not determine
definitively whether this patient expe-
rienced primary or secondary dengue.
In light of virologic tests results, the
diagnosis of secondary dengue infec-
tion was more likely (3).
A PubMed search using the key-
words dengue, mixed infections, dual
infections, simultaneous infections,
and concurrent infections retrieved 14
references published since 1958. In
most cases, concurrent infection was
with 2 dengue virus strains from 2 dif-
ferent serotypes in a single patient
(4,5). Only 6 published studies report-
ed concurrent infection with dengue
virus and a bacterium (Salmonella
typhi,  Shigella sonnei,  Leptospira
spp.) (6–8) or with a virus such as
Chikungunya virus (9).
To our knowledge, this is the first
report of mixed dengue–parasite
infection, dengue virus with P. falci-
parum. The authors previously ques-
tioned the accuracy of a serologic test
to diagnosis dengue fever in patients
experiencing malaria because reactiv-
ity was nonspecific on certain rapid
serologic assays (10); however, sero-
logic tests used in this study have
demonstrated good specificity (10),
and molecular tests are not prone to
such specificity problems. Classifying
this case as dengue hemorrhagic fever
is questionable since some of the
hemorrhagic signs may have been
caused by acute malaria. In cases of
concurrent infections involving a
dengue virus, questions related to the
influence of mixed infection on sever-
ity and prognosis are, therefore,
impossible to address because of lack
of information. Further investigations
are required because this situation
likely occurs frequently in nature,
despite scant available data.
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To the Editor: Roehrig and col-
leagues described the long-term per-
sistence of immunoglobulin (Ig) M
antibody in patients with West Nile
virus (WNV) infection, as tested
using an in-house Centers for Disease
Control and Prevention (CDC)
enzyme immunoassay (EIA) (1). This
result suggests that interpreting WNV
IgM results in subsequent years
would be difficult. With the commer-
cial availability and widespread use of
US Food and Drug Administration–LETTERS
approved WNV IgM tests, we were
concerned that this phenomenon
might also occur with new tests. Thus
in 2004, we initiated a follow-up
study of patients infected during the
inaugural (2003) WNV season in
Alberta, Canada.
Fifty patients who were WNV IgM
positive by 2 commercial IgM kits
(West Nile virus capture EIAs, Focus
Technologies, Cypress, CA, USA,
and Panbio, Windsor, Queensland,
Australia) during the fall of 2003 were
contacted. Sera were recollected and
tested for IgM and IgG antibodies to
WNV with current kits from these 2
companies. Sera were also tested for
hemagglutination-inhibiting (HI) anti-
bodies to WNV (2).
Of 39 serum samples from 38
patients, 28 were positive, 5 were inde-
terminate, and 6 were negative with
the Focus IgM kit. Twenty-one were
positive, 3 were indeterminate, and 14
were negative with the Panbio IgM kit.
All had WNV IgG antibodies detected
by Focus and Panbio IgG kits. We
detected HI antibodies to WNV in all
patients, and titers in 12 were >320.
The time course for IgM index values
for the Focus IgM kit used in 2003 and
2004 is shown in the Figure.
These data show that when tests are
conducted with newly available kits,
as with the CDC in-house test, IgM
antibody to WNV persists for ≥8
months in most patients. A single high
HI titer is not helpful in identifying
recent infection. In addition, the IgM
test cannot differentiate between
recent and past infections. Interpreting
a positive IgM result in WNV-endem-
ic areas will be complex because a
positive WNV IgM result could indi-
cate a current acute infection or a pre-
vious WNV infection even in a person
with a different acute illness.
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Hepatitis A, Italy
To the Editor: Hepatitis A virus
(HAV) infection rates are very low in
industrialized countries. A noticeable
fall in the prevalence of HAV antibod-
ies (anti-HAV) has been reported in
southern European and Mediterranean
countries such as Spain (1) and
Greece (2), reflecting improvements
in hygiene standards in the last
decades.
An HAV prevalence of 66.3% in
1981 (3) and 29.4% in 1990 (4) was
shown in studies conducted in mili-
tary recruits from all Italian regions.
In both studies, subjects from south-
ern regions had a higher HAV preva-
lence than those from north-central
regions. In 2003, we conducted a
study of recruits to show changes in
HAV infection prevalence in younger
Italian generations.
Military service was compulsory
in Italy at that time; all men 18–26
years of age were included. From
September to December 2003, 323
recruits 18–26 years of age (mean age
20 years), representing all Italian
regions, who had been accepted for
Air Force military service were tested
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 7, July 2005 1155
Figure. West Nile virus (WNV) immunoglobulin (Ig)M index values in serum specimens
from 38 WNV case-patients detected in the fall of 2003. The assay was performed by
using the Focus Technologies kit, as per the manufacturer’s instructions. An index >1.1
indicates a positive result and an index <0.9 indicates a negative result.